Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The investigators are studying a new treatment for one subtype of obesity. Obesity is not a
disease. It is a symptom of several different diseases. These diseases have distinct
etiologies, being caused by aberrations in different mechanisms. Forms of obesity caused by
such non-critical mechanisms might be corrected fairly easily and safely. The investigators
are interested in overeating and obesity that is caused by the opioidergic system. The
opioidergic system appears to be responsible for a subtype of obesity associated with binge
eating disorder (BED). People, especially with the right genetic predisposition, can become
addicted to foods that release endorphins, in the way that people become addicted to
exogenous opiates and other drugs that release endorphins. The particular application in our
proposed clinical trial is for intranasal (IN) naloxone. The peak levels of naloxone were
similar and the bioavailability of naloxone intranasally was 100% (the same) of that
available IV." IN administration of naloxone has since been broadly tested in humans, as
well, where it has been shown to be safe, with pharmacokinetics similar to those of naloxone
given by injection .